uMotif, a London-based eClinical startup, has raked in $25.5 million in fresh growth capital from Athyrium Capital Management, the parties tell Axios exclusively.
Why it matters: Digital capabilities and technology are increasingly catalyzing clinical research across both physical sites and decentralized trials, but study design is complex and historically taxing for patients participating.
